-+ 0.00%
-+ 0.00%
-+ 0.00%

Assembly Biosciences To Present New Phase 1a Data From Its ABI-6250 Program At The Liver Meeting 2026

Benzinga·10/05/2026 14:01:19
Listen to the news

Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced that two posters featuring new Phase 1a data from its ABI-6250 program will be presented at The Liver Meeting® 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 5-9, 2026, in Denver, Colorado.